SCHEMBL2563853

SCHEMBL2563853

COc1ccc(-c2nc(OCCN3CC[C@H](F)C3)nc3[nH]cc(C#N)c23)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 7/20 0.60
KCNH2 Q12809 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CHUK O15111 4/20 0.38
KDM1A O60341 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
TLR9 Q9NR96 1/20 0.36
ACVR1 Q04771 1/20 0.36
IKBKB O14920 2/20 0.36
MAP4K1 Q92918 1/20 0.36
KIT P10721 1/20 0.36
HSP90AA1 P07900 1/20 0.36
RET P07949 1/20 0.36
KIF5B P33176 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2563850 1.00 HSP90AB1 (0.60) HSP90AB1KCNH2LRRK2CHUKKDM1A
SCHEMBL2568036 0.87 HSP90AB1 (0.55) HSP90AB1KCNH2LRRK2CHUKMAP4K1
SCHEMBL12161026 0.86 HSP90AB1 (0.80) HSP90AB1KCNH2HSP90AA1
SCHEMBL12160981 0.86 HSP90AB1 (0.80) HSP90AB1KCNH2HSP90AA1
SCHEMBL2568902 0.85 HSP90AB1 (0.61) HSP90AB1KCNH2LRRK2CHUKMAP4K1
SCHEMBL4124013 0.83 HSP90AB1 (0.74) HSP90AB1KCNH2HSP90AA1
SCHEMBL4124014 0.83 HSP90AB1 (0.74) HSP90AB1KCNH2HSP90AA1
SCHEMBL13798717 0.81 HSP90AB1 (0.72) HSP90AB1KCNH2HSP90AA1
SCHEMBL13798715 0.81 HSP90AB1 (0.69) HSP90AB1KCNH2HSP90AA1
SCHEMBL2568988 0.80 HSP90AB1 (0.57) HSP90AB1KCNH2ACVR1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007767-B1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS R&D LTD (GB) 2011-11-02 EP disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed
EP-2007767-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R&D) LTD (GB) 2008-12-31 EP disclosed
WO-2007104944-A1 PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS VERNALIS (R & D) LTD. (GB) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors HSP90AA1, HSP90AB1, RAF1 HSP90AB1 2/4885KCNH2 2202/4885LRRK2 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.